Form 4: Vericel Corp CEO Dominick Colangelo Reports Stock Transactions Following RSU Vesting

Dominick Colangelo, President and CEO of Vericel Corp, reports the acquisition and disposal of common stock and restricted stock units (RSUs) following recent vesting events.

Summary

• On February 18 and 19, 2025, Dominick Colangelo, the President and CEO of Vericel Corp, engaged in transactions involving the company's common stock and restricted stock units (RSUs).
• These transactions were primarily related to the vesting of RSUs granted in previous years.
• On February 18, 2025, 18,250 RSUs vested from a grant on February 17, 2023, resulting in the acquisition of 18,250 shares of common stock, which were then deferred into phantom stock units under the Vericel Corporation Deferred Compensation Plan.
• An additional 11,700 RSUs vested from a grant on February 18, 2022, resulting in the acquisition of 11,700 shares of common stock.
• Also on February 18, 2025, 5,423 shares were withheld by the issuer to cover tax obligations related to the RSU vesting, at a price of $57.28 per share.
• On February 19, 2025, 8,938 RSUs vested from a grant on February 19, 2021, resulting in the acquisition of 8,938 shares of common stock.
• An additional 4,196 shares were withheld by the issuer to cover tax obligations related to the RSU vesting, at a price of $57.78 per share.
• Following these transactions, Colangelo directly owns 250,206 shares of Vericel Corp common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the document primarily reports routine transactions related to executive compensation. There are no indications of significant positive or negative developments.

Positives

• The vesting of RSUs indicates that Colangelo has met certain performance or time-based milestones set by the company.
• The deferred compensation plan allows Colangelo to defer taxes on the vested shares, potentially benefiting from future stock appreciation.

Negatives

• The sale of shares to cover tax obligations reduces Colangelo's overall stake in the company, although this is a common practice.

Risks

• The value of the deferred phantom stock units is tied to the future performance of Vericel Corp's common stock, which is subject to market risks.
• Changes in tax laws could impact the benefits of the deferred compensation plan.

Industry Context

Executive compensation packages often include RSUs to align management's interests with those of shareholders, and the vesting of these units is a routine event.

Comparison to Industry Standards

• RSU grants are a common form of executive compensation in the biotechnology and pharmaceutical industries, similar to companies like CRISPR Therapeutics and Vertex Pharmaceuticals.
• The vesting schedules and terms of these grants are typically benchmarked against industry peers to attract and retain top talent.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are part of the executive compensation plan.
• Shareholders may view the vesting of RSUs as a sign that management is incentivized to improve company performance.

Next Steps

• Remaining RSUs from the February 17, 2023 grant will vest in annual installments on February 17, 2026, and February 17, 2027.
• Remaining RSUs from the February 18, 2022 grant will vest on February 18, 2026.

Key Dates